文献速递瓣膜病与结构性心脏病

低风险患者经导管与外科主动脉瓣置换术后2年结局

2-Year Outcomes After Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients.
PubMed 文献 · J Am Coll Cardiol · 2022-01-01

Evolut Low Risk试验将1414例低外科风险的重度主动脉瓣狭窄患者随机分配至TAVR或外科AVR,完整2年随访显示TAVR在全因死亡或致残性卒中的主要终点上不劣于外科手术,事件率略优于贝叶斯分析预测值。

要点

  • 低风险重度主动脉瓣狭窄患者中,TAVR术后2年主要终点事件率不劣于外科AVR。
  • TAVR组与外科组2年全因死亡或致残性卒中发生率分别为4.3%和6.3%(P=0.084)。
  • 第1年至第2年间主要终点生存曲线无收敛趋势。

核心结论

  • 在低外科风险的重度主动脉瓣狭窄患者中,完整2年随访证实TAVR在全因死亡或致残性卒中主要终点上不劣于外科主动脉瓣置换。

研究设计与样本

  • 多中心随机对照试验Evolut Low Risk Trial,共1414例低外科风险重度主动脉瓣狭窄患者随机接受TAVR或外科AVR。
  • 不良事件由独立临床事件委员会裁定,血流动力学终点由中心超声核心实验室评估。
  • 2016年3月至2019年5月,TAVR组730例、外科组684例尝试植入。

主要发现

  • 完整2年主要终点(死亡或致残性卒中)Kaplan-Meier率TAVR组4.3%、外科组6.3%(P=0.084)。
  • 全因死亡率TAVR组3.5%、外科组4.4%(P=0.366);致残性卒中率分别为1.5%和2.7%(P=0.119)。
  • 中期贝叶斯分析主要终点率TAVR组5.3%、外科组6.7%(差值-1.4%,95%贝叶斯可信区间-4.9%至2.1%)。
  • 第1年至第2年间主要终点生存曲线无收敛。

临床怎么用

  • 对于低外科风险的重度主动脉瓣狭窄患者,TAVR可作为外科AVR之外的合理选择,2年结局支持其不劣于外科手术。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The Evolut Low Risk Trial (Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients) showed that transcatheter aortic valve replacement (TAVR) with a supra-annular, self-expanding valve was noninferior to surgery for the primary endpoint of all-cause mortality or disabling stroke at 2 years. This finding was based on a Bayesian analysis performed after 850 patients had reached 1 year of follow-up. OBJECTIVES: The goal of this study was to report the full 2-year clinical and echocardiographic outcomes for patients enrolled in the Evolut Low Risk Trial. METHODS: A total of 1,414 low-surgical risk patients with severe aortic stenosis were randomized to receive TAVR or surgical AVR. An independent clinical events committee adjudicated adverse events, and a central echocardiographic core laboratory assessed hemodynamic endpoints. RESULTS: An attempted implant was performed in 730 TAVR and 684 surgical patients from March 2016 to May 2019. The Kaplan-Meier rates for the complete 2-year primary endpoint of death or disabling stroke were 4.3% in the TAVR group and 6.3% in the surgery group (P = 0.084). These rates were comparable to the interim Bayesian rates of 5.3% with TAVR and 6.7% with surgery (difference: -1.4%; 95% Bayesian credible interval: -4.9% to 2.1%). All-cause mortality rates were 3.5% vs 4.4% (P = 0.366), and disabling stroke rates were 1.5% vs 2.7% (P = 0.119), respectively. Between years 1 and 2, there was no convergence of the primary outcome curves. CONCLUSIONS: The complete 2-year follow-up from the Evolut Low Risk Trial found that TAVR is noninferior to surgery for the primary endpoint of all-cause mortality or disabling stroke, with event rates that were slightly better than those predicted by using the Bayesian analysis. (Medtronic Evolut Transcatheter Aortic Valve Replacement in Low Risk Patients [Evolut Low Risk Trial]; NCT02701283).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Forrest JK, Deeb GM, Yakubov SJ, et al. 2-Year Outcomes After Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients. J Am Coll Cardiol. 2022. PMID: 35241222. doi:10.1016/j.jacc.2021.11.062

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。